These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 28746779)

  • 21. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.
    Yao J; Zhou CS; Ma X; Fu BQ; Tao LS; Chen M; Xu YP
    World J Gastroenterol; 2014 Oct; 20(39):14430-41. PubMed ID: 25339829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid.
    Walters JR; Johnston IM; Nolan JD; Vassie C; Pruzanski ME; Shapiro DA
    Aliment Pharmacol Ther; 2015 Jan; 41(1):54-64. PubMed ID: 25329562
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.
    Puri P; Daita K; Joyce A; Mirshahi F; Santhekadur PK; Cazanave S; Luketic VA; Siddiqui MS; Boyett S; Min HK; Kumar DP; Kohli R; Zhou H; Hylemon PB; Contos MJ; Idowu M; Sanyal AJ
    Hepatology; 2018 Feb; 67(2):534-548. PubMed ID: 28696585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating microbiota-derived metabolites: a "liquid biopsy?
    Aragonès G; Colom-Pellicer M; Aguilar C; Guiu-Jurado E; Martínez S; Sabench F; Antonio Porras J; Riesco D; Del Castillo D; Richart C; Auguet T
    Int J Obes (Lond); 2020 Apr; 44(4):875-885. PubMed ID: 31388096
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improvement of NASH and liver fibrosis through modulation of the gut-liver axis by a novel intestinal FXR agonist.
    Moon AN; Briand F; Breyner N; Song DK; Madsen MR; Kim H; Choi K; Lee Y; Namkung W
    Biomed Pharmacother; 2024 Apr; 173():116331. PubMed ID: 38428307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.
    Harrison SA; Bashir MR; Lee KJ; Shim-Lopez J; Lee J; Wagner B; Smith ND; Chen HC; Lawitz EJ
    J Hepatol; 2021 Jul; 75(1):25-33. PubMed ID: 33581174
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
    Loomba R; Sanyal AJ; Kowdley KV; Terrault N; Chalasani NP; Abdelmalek MF; McCullough AJ; Shringarpure R; Ferguson B; Lee L; Chen J; Liberman A; Shapiro D; Neuschwander-Tetri BA
    Gastroenterology; 2019 Jan; 156(1):88-95.e5. PubMed ID: 30222962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    Ijssennagger N; Janssen AWF; Milona A; Ramos Pittol JM; Hollman DAA; Mokry M; Betzel B; Berends FJ; Janssen IM; van Mil SWC; Kersten S
    J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease.
    Grimaudo S; Dongiovanni P; Pihlajamäki J; Eslam M; Yki-Järvinen H; Pipitone RM; Baselli G; Cammà C; Di Marco V; Enea M; Longo M; Pennisi G; Prati D; Zito R; Fracanzani AL; Craxì A; George J; Romeo S; Valenti L; Petta S
    Liver Int; 2021 Nov; 41(11):2712-2719. PubMed ID: 34268860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice.
    Hartmann P; Hochrath K; Horvath A; Chen P; Seebauer CT; Llorente C; Wang L; Alnouti Y; Fouts DE; Stärkel P; Loomba R; Coulter S; Liddle C; Yu RT; Ling L; Rossi SJ; DePaoli AM; Downes M; Evans RM; Brenner DA; Schnabl B
    Hepatology; 2018 Jun; 67(6):2150-2166. PubMed ID: 29159825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.
    Mouzaki M; Wang AY; Bandsma R; Comelli EM; Arendt BM; Zhang L; Fung S; Fischer SE; McGilvray IG; Allard JP
    PLoS One; 2016; 11(5):e0151829. PubMed ID: 27203081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bile acids override steatosis in farnesoid X receptor deficient mice in a model of non-alcoholic steatohepatitis.
    Wu W; Liu X; Peng X; Xue R; Ji L; Shen X; Chen S; Gu J; Zhang S
    Biochem Biophys Res Commun; 2014 May; 448(1):50-5. PubMed ID: 24747563
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease.
    Pacifico L; Bonci E; Marandola L; Romaggioli S; Bascetta S; Chiesa C
    World J Gastroenterol; 2014 Dec; 20(45):17107-14. PubMed ID: 25493023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lean NAFLD: A Distinct Entity Shaped by Differential Metabolic Adaptation.
    Chen F; Esmaili S; Rogers GB; Bugianesi E; Petta S; Marchesini G; Bayoumi A; Metwally M; Azardaryany MK; Coulter S; Choo JM; Younes R; Rosso C; Liddle C; Adams LA; Craxì A; George J; Eslam M
    Hepatology; 2020 Apr; 71(4):1213-1227. PubMed ID: 31442319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Farnesoid X receptor-dependent and -independent pathways mediate the transcriptional control of human fibroblast growth factor 19 by vitamin A.
    Jahn D; Sutor D; Dorbath D; Weiß J; Götze O; Schmitt J; Hermanns HM; Geier A
    Biochim Biophys Acta; 2016 Feb; 1859(2):381-92. PubMed ID: 26723851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant PPARα and FXR Activation as a Putative Mechanism of NASH Improvement after Gastric Bypass Surgery: a GEO Datasets Analysis.
    Mazzini GS; Khoraki J; Dozmorov M; Browning MG; Wijesinghe D; Wolfe L; Gurski RR; Campos GM
    J Gastrointest Surg; 2019 Jan; 23(1):51-57. PubMed ID: 30206765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.
    Adorini L; Pruzanski M; Shapiro D
    Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of docosahexaenoic acid-choline-vitamin E in paediatric NASH: a randomized controlled clinical trial.
    Zöhrer E; Alisi A; Jahnel J; Mosca A; Della Corte C; Crudele A; Fauler G; Nobili V
    Appl Physiol Nutr Metab; 2017 Sep; 42(9):948-954. PubMed ID: 28511023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The gut-liver axis in hepatocarcinoma: a focus on the nuclear receptor FXR and the enterokine FGF19.
    Piglionica M; Cariello M; Moschetta A
    Curr Opin Pharmacol; 2018 Dec; 43():93-98. PubMed ID: 30223181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH.
    Boga S; Koksal AR; Alkim H; Yilmaz Ozguven MB; Bayram M; Ergun M; Sisman G; Tekin Neijmann S; Alkim C
    Metab Syndr Relat Disord; 2015 Nov; 13(9):393-9. PubMed ID: 26367098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.